Molecular profiling and risk classification of patients with myeloproliferative neoplasms and splanchnic vein thromboses

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study

(2020) Heinz Gisslinger et al.   Lancet Haematology

Prevalence and phenotypes of JAK2 V617F and calreticulin mutations in a Danish general population

(2019) Sabrina Cordua et al.   BLOOD

From Budd-Chiari syndrome to acquired von Willebrand syndrome: thrombosis and bleeding complications in the myeloproliferative neoplasms

(2019) Brady L. Stein et al.   Hematology-American Society of Hematology Education Program

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet

(2018) Tiziano Barbui et al.   LEUKEMIA

Prevalence of CALR mutations in splanchnic vein thrombosis: A systematic review and meta-analysis

(2018) Miaomiao Li et al.   THROMBOSIS RESEARCH

Classification and Personalized Prognosis in Myeloproliferative Neoplasms

(2018) Jacob Grinfeld et al.   NEW ENGLAND JOURNAL OF MEDICINE

Selective testing for calreticulin gene mutations in patients with splanchnic vein thrombosis: A prospective cohort study

(2017) Johanne Poisson et al.   JOURNAL OF HEPATOLOGY

Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease

(2017) Siddhartha Jaiswal et al.   NEW ENGLAND JOURNAL OF MEDICINE

EASL Clinical Practice Guidelines: Vascular diseases of the liver

(2016)   JOURNAL OF HEPATOLOGY

JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: Clinical usefulness for predicting myelofibrotic transformation and thrombotic events

(2014) Alberto Alvarez-Larrán et al.   AMERICAN JOURNAL OF HEMATOLOGY

Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms

(2014) P. Lundberg et al.   BLOOD

Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis

(2013) F. Cervantes et al.   BLOOD

Somatic CALR Mutations in Myeloproliferative Neoplasms with Nonmutated JAK2

(2013) J. Nangalia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Somatic Mutations of Calreticulin in Myeloproliferative Neoplasms

(2013) Thorsten Klampfl et al.   NEW ENGLAND JOURNAL OF MEDICINE

Myeloproliferative neoplasms in Budd-Chiari syndrome and portal vein thrombosis: a meta-analysis

(2012) J. H. Smalberg et al.   BLOOD

Management of hepatic vascular diseases

(2012) Aurélie Plessier et al.   JOURNAL OF HEPATOLOGY

Age-related differences in disease characteristics and clinical outcomes in polycythemia vera

(2012) Brady L. Stein et al.   LEUKEMIA & LYMPHOMA

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

(2009) J. W. Vardiman et al.   BLOOD

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment)

(2009) F. Passamonti et al.   BLOOD

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

(2008) J.-J. Kiladjian et al.   BLOOD